GSK Partners With Canadian Biotech Medicago on COVID-19 Vaccine

GlaxoSmithKline (GSK) is collaborating with the Canadian biotech firm Medicago  to develop a COVID-19 vaccine.

The companies plan to start a phase 1 clinical trial of the vaccine this month, evaluating three different doses 21 days apart. GSK and Medicago also plan to manufacture 100 million doses of the vaccine by the end of 2021 and to deliver up to 1 billion doses annually starting in 2023. — Jordan Williams